Learn about toxic megacolon, a serious complication of IBD. Discover its causes, symptoms, diagnosis, treatment, and ...

Microbiotica has completed patient recruitment for its phase 1b trial, COMPOSER-1, evaluating MB310 in adults with ulcerative ...

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live ...

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

Researchers from The University of Osaka reveal that the intestinal flora works in combination with the mutated OTUD3 gene ...

If you’re craving veggies at a restaurant, opt for cooked ones rather than raw. Raw veggies are often more difficult to ...

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

The interaction between a common gene variant and gut microbes may trigger chronic inflammation in ulcerative colitis, new research suggests.

Histologic remission is recommended as an adjunctive treatment target in ulcerative colitis, and scoring systems have been proposed to enhance ...

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

Results from the Phase III ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) trials showed that Abivax’s obefazimod demonstrated significant clinical remission in patients with ulcerative colitis.

A real-world study from China shows vedolizumab is safe and effective for elderly patients with ulcerative colitis, with ...